Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning Tablet for Coronary Microcirculation After PPCI in STEMI
NCT07621107Phase 2Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2027
01
Overview
Phase 2, randomised, double-blind trial of Guanxinning Tablet in ST elevation myocardial infarction (STEMI) and Coronary Microvascular Dysfunction (CMD) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Change in intramyocardial hemorrhage volume at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
Guanxinning Tablet
03
Conditions
ST elevation myocardial infarction (STEMI)Coronary Microvascular Dysfunction (CMD)
Beyond the preview
Go deeper on NCT07621107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621107.